A mounted-duration, first-line combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) looked doubtless for chronic lymphocytic leukemia (CLL) patients who accomplished undetectable minimal residual disease (MRD)…
A mounted-duration, first-line combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) looked doubtless for chronic lymphocytic leukemia (CLL) patients who accomplished undetectable minimal residual disease (MRD)…